04.2020 SARomics Biostructures, Red Glead Discovery and researchers at Sahlgrenska Cancer Center jointly collaborate in this project that was one of 15 financed by Swelife in order to increase health and well- being as well as increasing the sustainable growth and competitiveness of Swedish life science. In the project, a preclinical innovative epigenetic therapy will be significantly advanced towards clinical studies for an orphan cancer indication. Press release…
02.2020 Aqilion AB contracts integrated drug discovery project with SARomics Biostructures and Red Glead Discovery. The aim of the project is to develop drug candidates that bind to a target protein that is essential for both malignant disease development and for inflammatory conditions. A successful project can therefore help to develop new medications to treat orphan drug indications in the field of autoinflammatory diseases, as well as new combination therapies within the field of oncology, primarily intestinal cancer. Read more…
01.2020 SARomics Biostructures will assist Follicum AB to study FOL peptide binding to receptors on pancreatic cells. The new research will broaden the knowledge base within the company's project aimed at the development of a peptide-based treatment for diabetes. The project will study FOL peptide binding to the surface receptors / targets previously identified on pancreatic cells to investigate how this binding results in an increase in insulin secretion at the same time as the pancreatic cells are protected and preserved.. Read more… 07.2019 SARomics Biostructures and Red Glead Discovery acquire the weak-affinity chromatography (WAC™) technology from Transientic Interactions AB. Press release… (in Swedish)
10.2018 SARomics Biostructures will use its 3D structure determination capabilities to assist Alligator Bioscience AB, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, to verify the unique functionality of ATOR-1017, an immuno-stimulatory antibody in development for the treatment of metastatic cancer. Read more…
10.2017 University of Copenhagen, SARomics Biostructures and Enamine join forces to develop the next generation of safer anti-depressants in an EU-funded project Selective Agonists For Serotonin Receptors (SAFER). Read more… or visit project site SAFER 08.2016 SARomics Biostructures & Carna Biosciences sign exclusive distribution agreement covering the Japanese market, Press release…
03.2015 SARomics Biostructures opens U.S. sales office! Press release…
01.2014 SARomics Biostructures and Xbrane Bioscience form a strategic partnership for “off-the-shelf” protein structures, Press release...
02.2014 SARomics Biostructures and BioVersys join efforts to combat multidrug-resistant bacterial infections, Press release...
03.2014 SARomics Biostructures first Nordic company to obtain growth capital through a collaborative initiative between Sparbanken Öresund and the European Investment Fund, Press release…
04.2013 SARomics Biostructures coordinates an EU-funded industry-academia drug discovery partnership, Press release...
10.2012 SARomics Biostructures and Red Glead Discovery enter lead discovery collaboration in the field of epigenetic disorders, Press release...
09.2012 SARomics Biostructures brings in new strategic owners, Press release...
12.2010 Inimex Pharmaceuticals and SARomics Biostructures Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration. Press release... 09.2009 UNIZYME Laboratories and SARomics enter into drug discovery collaboration press release 09.2007 SARomics and Alligator Bioscience, Lund, have entered into a collaboration agreement. Press Release